Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie K Jones

Showing results (21-30 of 157) with videos related to

Pageof 16
Sort By:
Neuropharmacology|July 7, 2005
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosingCarrie K Jones, Elizabeth Lutz Eberle, Stephen C Peters, et al.
The European Journal of Neuroscience|May 26, 2020
Sexual Dimorphism in Stress-induced Hyperthermia in SNAP25Δ3 mice, a mouse model with disabled Gβγ regulation of the exocytotic fusion apparatusAnalisa D Thompson Gray, Justice Simonetti, Feyisayo Adegboye, et al.
Neuropharmacology|January 31, 2023
Selective M<sub>5</sub> muscarinic acetylcholine receptor negative allosteric modulator VU6008667 blocks acquisition of opioid self-administrationLaura B Teal, Michael Bubser, Edith Duncan, et al.
Addiction Biology|October 19, 2017
Selective inhibition of M<sub>5</sub> muscarinic acetylcholine receptors attenuates cocaine self-administration in ratsBarak W Gunter, Robert W Gould, Michael Bubser, et al.
Pain|August 22, 2001
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in ratsHarlan E Shannon, Carrie K Jones, Dominic L Li, et al.
Nuclear Medicine and Biology|October 31, 2009
[(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plotMohammed N Tantawy, Carrie K Jones, Ronald M Baldwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 11, 2018
Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M<sub>4</sub> Muscarinic Receptor as a Novel Therapeutic TargetRocco G Gogliotti, Nicole M Fisher, Branden J Stansley, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studiesKevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives|June 4, 2010
The antipsychotic potential of muscarinic allosteric modulationThomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2006
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in miceRuggero Galici, Carrie K Jones, Kamondanai Hemstapat, et al.
Pageof 16

Showing results (21-30 of 157) with videos related to

Sort By:
Pageof 16
Neuropharmacology|July 7, 2005
Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosingCarrie K Jones, Elizabeth Lutz Eberle, Stephen C Peters, et al.
The European Journal of Neuroscience|May 26, 2020
Sexual Dimorphism in Stress-induced Hyperthermia in SNAP25Δ3 mice, a mouse model with disabled Gβγ regulation of the exocytotic fusion apparatusAnalisa D Thompson Gray, Justice Simonetti, Feyisayo Adegboye, et al.
Neuropharmacology|January 31, 2023
Selective M<sub>5</sub> muscarinic acetylcholine receptor negative allosteric modulator VU6008667 blocks acquisition of opioid self-administrationLaura B Teal, Michael Bubser, Edith Duncan, et al.
Addiction Biology|October 19, 2017
Selective inhibition of M<sub>5</sub> muscarinic acetylcholine receptors attenuates cocaine self-administration in ratsBarak W Gunter, Robert W Gould, Michael Bubser, et al.
Pain|August 22, 2001
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in ratsHarlan E Shannon, Carrie K Jones, Dominic L Li, et al.
Nuclear Medicine and Biology|October 31, 2009
[(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plotMohammed N Tantawy, Carrie K Jones, Ronald M Baldwin, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 11, 2018
Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M<sub>4</sub> Muscarinic Receptor as a Novel Therapeutic TargetRocco G Gogliotti, Nicole M Fisher, Branden J Stansley, et al.
Bioorganic & Medicinal Chemistry Letters|February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studiesKevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives|June 4, 2010
The antipsychotic potential of muscarinic allosteric modulationThomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2006
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in miceRuggero Galici, Carrie K Jones, Kamondanai Hemstapat, et al.
Pageof 16